Emma -

Genetic Solutions > Emma

Overview

EMMA
Benefits
Indications

What is the EMMA test?

EMMA is a test that analyses the endometrial microbiome to help identify abnormalities associated with a poor reproductive prognosis.
EMMA indicates the endometrial microbiome balance, providing information on the proportions of all endometrial bacteria, including those linked to higher pregnancy rates. EMMA also includes ALICE, which detects pathogenic bacteria that can cause chronic endometritis.

What is the procedure?

EMMA can be performed on a small piece of an endometrial biopsy.

Why use EMMA test?

EMMA uses the latest Next Generation Sequencing (NGS) technology to provide endometrial microbiome information by analysing the complete profile of the bacteria present in the tissue
EMMA can determine the percentage of Lactobacillus present in the endometrium; low proportions of Lactobacillus are associated with poor reproductive outcomes
EMMA includes the ALICE test, so it indicates the possible presence of bacteria that can cause chronic endometritis, further other pathogenic bacteria.
If the endometrium is non-Lactobacillus dominated, the report will suggest the adequate treatment for each patient
EMMA will determine whether the uterine microbial environment is optimal or not for embryo implantation

Who should use the EMMA test?

Patients with repeated implantation failure (RIF)
EMMA can be beneficial for any patient wishing to conceive, by assessing the microbiological environment that the embryo will encounter at implantation

*Moreno et al., 2016

Test Limitations

These tests are not able to detect resistance to antibiotics
The tests are not 100% accurate at determining the bacterial species.
A negative result doesn’t rule out the presence of other endometrial pathogens

Documentation

Specialists

Technical Sheets

Download

Brochure

Download

Acceptable OCPs for EMMA and ALICE Testing

Download

Scientific evidence

Relevant related studies:

Evidence that the endometrial microbiota has an effect on implantation success or failure. Moreno, Inmaculada et al. American Journal of Obstetrics & Gynecology, Volume 215, Issue 6, 684 – 703.

Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486:207–14.

If you´re a little lost with this technical information...

Can we help you?

I’m not a health specialist

Igenomix et la fertilité

Nous travaillons à créer un monde dans lequel l’infertilité n’est plus un obstacle impossible à surmonter. En collaboration avec des cliniques et des médecins spécialisés dans le domaine de la fertilité dans le monde entier, nous étudions la reproduction humaine pour changer la vie des couples qui essaient d’avoir un enfant.

Other services

ERA

Evaluates the endometrial receptivity

More information

EndomeTRIO

Improve the reproductive prognosis of your patients

More information

ALICE

Detects the bacteria causing chronic endometritis

More information

Igenomix is in the media

Igenomix is not affiliated with any news outlet or publication identified above. News coverage does not constitute an endorsement of Igenomix or its products.

20% of infertility is caused by the endometrial factor

30% of infertile women have pathogenic bacteria

What is the procedure?

Why use EMMA test?

Who should use the EMMA test?

Test Limitations

Technical Sheets

Brochure

Acceptable OCPs for EMMA and ALICE Testing

Relevant related studies:

Can we help you?

Igenomix et la fertilité

ERA

EMMA Endometrial Microbiome Metagenomic Analysis

A screening test to evaluate the endometrium at the microbiological level

20% of infertility is caused by the endometrial factor

30% of infertile women have pathogenic bacteria

What is the procedure?

Why use EMMA test?

Who should use the EMMA test?

Test Limitations

Technical Sheets

Brochure

Acceptable OCPs for EMMA and ALICE Testing

Relevant related studies:

Can we help you?

Igenomix et la fertilité

Other services

ERA

Igenomix is in the media